Peter Trenkwalder Selected Research

aliskiren

4/2009

Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Trenkwalder Research Topics

Disease

10	Hypertension (High Blood Pressure) 10/2015 - 01/2000
7	Stroke (Strokes) 10/2015 - 01/2000
3	Cognitive Dysfunction 08/2005 - 01/2000
1	Embolic Stroke 10/2015
1	Weight Loss (Weight Reduction) 10/2015
1	Edema (Dropsy) 04/2009
1	Cough 07/2008
1	Isolated Systolic Hypertension 09/2004
1	Dementia (Dementias) 05/2003
1	Essential Hypertension 05/2003
1	Heart Failure 01/2000
1	Diabetes Mellitus 01/2000
1	Atherosclerosis 01/2000
1	Myocardial Infarction 01/2000
1	Lung Diseases (Lung Disease) 01/2000
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2000

Drug/Important Bio-Agent (IBA)

6	Antihypertensive Agents (Antihypertensives)IBA 04/2009 - 01/2000
5	candesartanIBA 03/2006 - 05/2003
3	candesartan cilexetil (Amias)FDA Link 01/2002 - 01/2000
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2014 - 07/2008
2	DiureticsIBA 01/2004 - 01/2000
2	Valsartan (Vals)FDA Link 01/2004 - 05/2003
1	CholesterolIBA 10/2015
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2015
1	aliskiren FDA Link 04/2009
1	Amlodipine (Norvasc)FDA LinkGeneric 04/2009
1	Ramipril (Altace)FDA LinkGeneric 07/2008
1	Indapamide FDA LinkGeneric 09/2006
1	Perindopril FDA LinkGeneric 09/2006
1	Angiotensin IIIBA 09/2004
1	Angiotensin II Type 1 Receptor BlockersIBA 09/2004
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2004
1	Angiotensin Receptor AntagonistsIBA 01/2004
1	Glucose (Dextrose)FDA LinkGeneric 01/2000
1	CalciumIBA 01/2000
1	LipidsIBA 01/2000

Therapy/Procedure

8	Therapeutics 04/2009 - 01/2000
1	Secondary Prevention 10/2015